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LAPANG PANDANG KET 
1 2 3 4 5 
K1 1 2 2 2 1  
K2 2 4B 4B 4B 3  
K3 4B 4C 4B 4C 4A  
K4 3 3 3 4A 3  
K5 3 4C 4A 4A 4A  
       
P1.1 2 1 2 3 2  
P1.2 2 4A 4C 4B 4B  
P1.3 4B 4B 4C 4C 4B  
P1.4 4C 4B 4B 4B 4C  
P1.5 2 2 4A 2 2  
       
P2.1 2 1 2 1 3  
P2.2 0 1 0 1 1  
P2.3 4B 2 4C 0 1  
P2.4 4C 4B 4C 4C 4C  
P2.5 0 1 0 0 0  





Lampiran 3 Hasil Analisis SPSS 
 
kelompok * grade fibrosis 2 Crosstabulation 
 Grade Fibrosis 
Grade 0 Grade 1 
kelompok 
kontrol 
Count 0 2 
% within kelompok 0.0% 8.0% 
% within grade fibrosis 2 0.0% 20.0% 
% of Total 0.0% 2.7% 
UDCA 
Count 0 1 
% within kelompok 0.0% 4.0% 
% within grade fibrosis 2 0.0% 10.0% 
% of Total 0.0% 1.3% 
UDCA-Glutathione 
Count 7 7 
% within kelompok 28.0% 28.0% 
% within grade fibrosis 2 100.0% 70.0% 
% of Total 9.3% 9.3% 
Total 
Count 7 10 
% within kelompok 9.3% 13.3% 
% within grade fibrosis 2 100.0% 100.0% 




 Grade Fibrosis 
Grade 2 Grade 3 
kelompok kontrol 
Count 5 5 
% within kelompok 20.0% 20.0% 
% within grade fibrosis 2 31.2% 71.4% 




Count 8 1 
% within kelompok 32.0% 4.0% 
% within grade fibrosis 2 50.0% 14.3% 
% of Total 10.7% 1.3% 
UDCA-Glutathione 
Count 3 1 
% within kelompok 12.0% 4.0% 
% within grade fibrosis 2 18.8% 14.3% 
% of Total 4.0% 1.3% 
Total 
Count 16 7 
% within kelompok 21.3% 9.3% 
% within grade fibrosis 2 100.0% 100.0% 




 Grade Fibrosis 
Grade 4a Grade 4b 
kelompok 
kontrol 
Count 5 5 
% within kelompok 20.0% 20.0% 
% within grade fibrosis 2 71.4% 33.3% 
% of Total 6.7% 6.7% 
UDCA 
Count 2 8 
% within kelompok 8.0% 32.0% 
% within grade fibrosis 2 28.6% 53.3% 
% of Total 2.7% 10.7% 
UDCA-Glutathione 
Count 0 2 
% within kelompok 0.0% 8.0% 
% within grade fibrosis 2 0.0% 13.3% 
% of Total 0.0% 2.7% 
Total 
Count 7 15 
% within kelompok 9.3% 20.0% 
% within grade fibrosis 2 100.0% 100.0% 











Count 3 25 
% within kelompok 12.0% 100.0% 
% within grade fibrosis 2 23.1% 33.3% 
% of Total 4.0% 33.3% 
UDCA 
Count 5 25 
% within kelompok 20.0% 100.0% 
% within grade fibrosis 2 38.5% 33.3% 
% of Total 6.7% 33.3% 
UDCA-Glutathione 
Count 5 25 
% within kelompok 20.0% 100.0% 
% within grade fibrosis 2 38.5% 33.3% 
% of Total 6.7% 33.3% 
Total 
Count 13 75 
% within kelompok 17.3% 100.0% 
% within grade fibrosis 2 100.0% 100.0% 









 kelompok N Mean Rank 
grade fibrosis 2 
kontrol 25 41.58 
UDCA 25 45.06 
UDCA-Glutathione 25 27.36 






 grade fibrosis 2 
Chi-Square 9.519 
df 2 
Asymp. Sig. .009 
a. Kruskal Wallis Test 





 kelompok N Mean Rank Sum of Ranks 
grade fibrosis 2 
kontrol 25 24.04 601.00 
UDCA 25 26.96 674.00 




 grade fibrosis 2 
Mann-Whitney U 276.000 
Wilcoxon W 601.000 
Z -.724 
Asymp. Sig. (2-tailed) .469 





 kelompok N Mean Rank Sum of Ranks 
grade fibrosis 2 
kontrol 25 30.54 763.50 
UDCA-Glutathione 25 20.46 511.50 








 grade fibrosis 2 
Mann-Whitney U 186.500 
Wilcoxon W 511.500 
Z -2.472 
Asymp. Sig. (2-tailed) .013 





 kelompok N Mean Rank Sum of Ranks 
grade fibrosis 2 
UDCA 25 31.10 777.50 
UDCA-Glutathione 25 19.90 497.50 




 grade fibrosis 2 
Mann-Whitney U 172.500 
Wilcoxon W 497.500 
Z -2.763 
Asymp. Sig. (2-tailed) .006 
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